<DOC>
	<DOCNO>NCT00774852</DOCNO>
	<brief_summary>This study individual lupus develop complication kidney , lupus nephritis . The study determine whether add experimental medication abatacept standard cyclophosphamide therapy effective improve lupus nephritis standard cyclophosphamide therapy .</brief_summary>
	<brief_title>Abatacept Cyclophosphamide Combination Therapy Lupus Nephritis</brief_title>
	<detailed_description>Lupus nephritis inflammation kidney occur patient systemic lupus erythematosus ( SLE ) . It cause immune system attack kidney among serious complication SLE : left untreated cause long term damage kidney , case , result kidney failure . One common treatment lupus nephritis `` Euro-lupus '' therapy . In therapy , patient receive three different drug - cyclophosphamide , azathioprine prednisone - course several month . However , patient respond therapy many show improvement . In ACCESS trial lupus nephritis , experimental medication know abatacept added Euro-lupus therapy ass work well Euro-lupus therapy alone . Abatacept man-made protein suppress part immune system cause autoimmune disease . While abatacept experimental lupus , approve FDA treat rheumatoid arthritis . Abatacept also study use autoimmune disease , like multiple sclerosis type 1 diabetes . Participants ACCESS trial lupus nephritis receive bi-weekly intravenous infusion cyclophosphamide 3 month , take azathioprine tablet daily least 3 month . Abatacept placebo administer every 2 week initially , every 4 week least first 6 month . Treatment abatacept placebo azathioprine may continue remainder year . All participant take prednisone tablet daily entire study . Because ACCESS trial randomize , control study , participant 50-50 chance ( like flip coin ) receive abatacept . Others receive inactive , placebo form drug . Note however , participant receive Euro-lupus therapy . As blind ( mask ) study , neither participant study physician know group person assign . All participant undergo regular physical examination , medical history various blood urine test . Many test repeat throughout study . Participants ask attend 18 study visit first year , one study visit end second year . The study reimburse participant certain expense incur part study .</detailed_description>
	<mesh_term>Nephritis</mesh_term>
	<mesh_term>Lupus Nephritis</mesh_term>
	<mesh_term>Lupus Erythematosus , Systemic</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Azathioprine</mesh_term>
	<mesh_term>Abatacept</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<criteria>Diagnosis systemic lupus erythematosus ( SLE ) American College Rheumatology ( ACR ) criterion Active lupus nephritis ( define : kidney biopsy documentation within last 12 month use International Society Nephrology/Renal Pathology Society ( ISN/RPS ) classification proliferative nephritis , active urinary sediment , urine proteintocreatinine ratio &gt; 1 , low complement C3 ) Positive antinuclear antibody ( ANA ) test result time study entry End stage renal disease Use cyclophosphamide past year Neutropenia , thrombocytopenia , moderately severe anemia Active infection , include HIV , hepatitis B C History cancer , except carcinoma situ treat basal squamous cell carcinoma Pregnant breastfeeding</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>lupus</keyword>
	<keyword>systemic lupus erythematosus</keyword>
	<keyword>lupus nephritis</keyword>
	<keyword>SLE</keyword>
	<keyword>abatacept</keyword>
	<keyword>CTLA4</keyword>
	<keyword>CTLA4Ig</keyword>
	<keyword>glomerulonephritis</keyword>
</DOC>